| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 70.719 | 105.890 | - | - | - | - | - | - | - | - |
| Total Income - EUR | 80.585 | 114.709 | - | - | - | - | - | - | - | - |
| Total Expenses - EUR | 80.282 | 97.766 | - | - | - | - | - | - | - | - |
| Gross Profit/Loss - EUR | 303 | 16.944 | - | - | - | - | - | - | - | - |
| Net Profit/Loss - EUR | 303 | 14.392 | - | - | - | - | - | - | - | - |
| Employees | 0 | 0 | - | - | - | - | - | - | - | - |
Check the financial reports for the company - Genomark Pharmaceuticals Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.465 | 693 | - | - | - | - | - | - | - | - |
| Current Assets | 112.905 | 224.634 | - | - | - | - | - | - | - | - |
| Inventories | 40.841 | 73.773 | - | - | - | - | - | - | - | - |
| Receivables | 23.453 | 71.168 | - | - | - | - | - | - | - | - |
| Cash | 48.611 | 79.693 | - | - | - | - | - | - | - | - |
| Shareholders Funds | -6.331 | 8.126 | - | - | - | - | - | - | - | - |
| Social Capital | 45 | 45 | - | - | - | - | - | - | - | - |
| Debts | 120.700 | 217.202 | - | - | - | - | - | - | - | - |
| Income in Advance | 0 | 0 | - | - | - | - | - | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4774 - 4774" | |||||||||
| CAEN Financial Year |
4774
|
|||||||||
Comments - Genomark Pharmaceuticals Srl